SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst community discussions about token burns and potential price movements, with some users expressing bullish sentiment and calling for a push towards higher valuations. However, other users are reporting frustration with the token's recent performance, and highlighting concerns about broader market trends and the potential for a prolonged bear market. The conversation also includes mentions of alternative meme coins and their potential for growth.

Bounce Token

Bounce Token is trending as traders discuss its potential for a bull run and analyze its chart patterns for entry points. Community members are speculating on possible partnerships and future price movements, with some expressing frustration over its business model. Recent discussions also highlight the token's volatility and potential for both significant gains and losses.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending, with excitement building around its integration with Phantom Wallet. The community is discussing its potential for significant gains, with many noting "moon vibes" and encouraging others to buy in early. However, some users are urging caution, comparing it to other hyped tokens that ultimately declined.

MLN is the official token of Enzyme. Founded in 2017, Enzyme is the global infrastructure for tokenized finance. Enzyme provides industry leaders with a comprehensive suites of Vault-As-A-Service and Financial Instruments products to manage on-chain assets efficiently, optimize operational processes, and develop innovative financial strategies tailored to their unique goals and challenges.

Melon

Enthusiasm seems to be building around MLN, with community members pointing to its low supply and anticipating a significant price surge reminiscent of other recent pumps. Some are suggesting it's primed for a breakout, while others urge caution, citing potential manipulation and calling for due diligence. The coin's historical price movements and technical indicators are also being closely watched for signals.

GraniteShares ETF Trust - GraniteShares 2x Long INTC Daily ETF

GraniteShares 2x Long INTC Daily ETF

GraniteShares 2x Long INTC Daily ETF ($INTW) is trending as Intel's potential turnaround, driven by progress in its 18A process and customer engagement, gains traction within the investment community. Nvidia's investment in Intel has boosted confidence, with some anticipating Intel outperforming its peers. Bullish technical indicators and anticipation of a positive earnings report are contributing to the upward momentum.

Uranus DEX is an innovative decentralized exchange (DEX) built on the Solana blockchain, designed as a permissionless, player-versus-player (PvP) prediction market platform. Unlike traditional DEXs that rely on automated market makers (AMMs) or liquidity pools, Uranus DEX offers a unique model where users can make long or short predictions on the price movements of any Solana-based token, including real-world assets (RWAs). This community-driven platform enables traders to engage directly from their crypto wallets, creating a transparent and accessible trading experience.  Built on Solana’s high-throughput, low-cost blockchain, Uranus DEX delivers fast transactions with minimal fees, appealing to both novice and seasoned traders. Its permissionless design allows users to speculate on any listed Solana token without restrictions, fostering a competitive PvP environment for price predictions. This flexibility empowers users to engage in dynamic trading battles, making it a standout in the decentralized finance (DeFi) space.  The native token, $URA, is integral to the ecosystem, supporting staking, governance, and community rewards. Trading fees are used to buy and vault $URA tokens, which are then allocated to liquidity events, ensuring platform sustainability and incentivizing participation. Uranus DEX enhances user accessibility by integrating with social platforms like X, allowing seamless trading through intuitive interfaces, broadening its appeal and engagement.  The platform has gained traction in the crypto community, notably through its participation in the Bonk Hackathon and milestones like reaching 1,000 followers on X. Positioned as a first mover in PvP prediction markets, Uranus DEX aims to democratize DeFi with a scalable, user-centric approach. Its smart contracts are verifiable on Solana’s blockchain explorer, ensuring transparency and security for users.  As with any DeFi platform, users should exercise caution, verify contract addresses, and be aware of risks such as price slippage and market volatility. For more details, visit uranus.today to explore the platform’s features, tokenomics, and community initiatives. Uranus DEX redefines decentralized trading by combining Solana’s technical efficiency with a bold vision for accessible, community-driven prediction markets.

The URA ETF is trending amid discussions of a potential breakout and bullish technical patterns, particularly related to Elliott Wave analysis, with community members highlighting its momentum. Interest is further fueled by news surrounding uranium security and the broader nuclear energy sector, with some traders pointing to specific stocks within the ETF. The ETF's composition, including significant holdings like OKLO, is also a point of discussion.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending as the community anticipates the mainnet launch and a potential Coinbase listing. Discussions revolve around its potential to connect all blockchains and banks, rivaling established cryptos like XRP and SOL. Speculation about major partnerships and its unique 'anchor' technology are also fueling the conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members discuss its potential, particularly the strength of its meme coin economy and upcoming partnerships. Several Solana-based tokens, like $PJ and $PEPEK, are gaining traction within the Phantom Wallet ecosystem. Traders are also watching for potential breakout patterns and the possibility of a Solana ETF.

The Hershey Co. engages in the manufacture and marketing of chocolate, sweets, mints and confectionery products. The firm operates through the following segments: North America Confectionery, North America Salty Snacks and International. The North America Confectionery segment is responsible for the traditional chocolate and non-chocolate confectionery market position of the company, as well as its grocery and snacks market positions, in the United States and Canada. The North America Salty Snacks segment is responsible for the salty snack products in the United States. The International segment includes the combination of all other operating segments, including those geographic regions where the company operates outside of North America. Its brands include Hershey's, Reese's, and Kisses. The company was founded by Milton S. Hershey in 1894 and is headquartered in Hershey, PA.

Hershey Company

Hershey is trending amidst speculation of a potential acquisition by Mondelez, driving significant price movement. The community is weighing the likelihood of a deal, considering Hershey's trust structure and previous rejected offers, while analysts are assessing the potential impact of rising cocoa prices and evolving consumer preferences on the company's future.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is trending due to updated analyst ratings and discussions around its commercial launch and potential market volatility. The community is weighing perspectives on management's performance, margin improvement plans, and buyout possibilities, particularly in light of its partnership with Johnson & Johnson. High short interest and unusual options activity are also fueling speculation about a potential squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy

Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and extended gains after-hours after the company said it was exploring strategic alternatives.&nbsp;The cancer drug developer said its options included a merger, acquisition, partnership, or licensing deal to advance its pipeline and maximize shareholder value.&nbsp;The company has retained MTS Health Partners to assist with the process.CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat showing a six-month survival benefit in advanced liver cancer and FDA clearance for a pivotal Phase 3 study.&nbsp;However, Brady said capital markets "have been unavailable to support the next stage of advancement."On Stocktwits, sentiment for Tempest surged into the 'extremely bullish' zone from 'neutral' a day ago, accompanied by message volume soaring over 135% in the 24 hours to late Wednesday.<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/TPST_sentiment_and_message_volume_April_9_png_4939200400.webp" alt="TPST sentiment and message volume April 9.png" width="1318" height="316"><figcaption>TPST sentiment and message volume April 9. | source: Stocktwits</figcaption></figure>One user said the CEO was "soliciting bidders" through this move following the recent 1-for-13 reverse stock split."Poison pill is still at $25. Now, anyone who wants more than a 10 percent ownership stake can buy whatever they want at $25 or more. Well played, Mr. Brady!" they wrote.<stembedurl>https://stocktwits.com/xyz1232/message/611152790</stembedurl>Another pinned hopes on "well-known" MTS Partners fetching a good merger deal for Tempest. "Even If TPST gets a below-average deal at $360 million, we're still looking at $100 per share."<stembedurl>https://stocktwits.com/GreylockSec/message/611168891</stembedurl>Amezalpat, Tempest's lead candidate, has received both Orphan Drug and Fast Track designations from the FDA.&nbsp;TPST-1495, a dual EP2/EP4 antagonist, is also advancing toward a Phase 2 trial in familial adenomatous polyposis (FAP) with NCI support.<a href="https://stocktwits.com/symbol/TPST">Tempest Therapeutics stock</a> has lost over 34% this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger

CEO Stephen Brady emphasized the company's strong data and regulatory momentum, pointing to Phase 2 results for amezalpat in advanced liver cancer and FDA clearance for a pivotal Phase 3 study. 

Equity

Why Is Small-Cap Tempest Therapeutics Stock Trading Higher On Thursday?

Tempest Therapeutics receives FDA feedback on the Phase 3 trial design for amezalpat (TPST-1120) in combination with Tecentriq and Avastin to treat first-line hepatocellular carcinoma. Study to begin...

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Tempest Therapeutics shares drop 13% to $2.48 on Thursday despite promising new data from its Phase 1b/2 study. The study shows a six-month survival improvement in hepatocellular carcinoma patients...

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

Glancy Prongay & Murray LLP (GPM) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its directors and officers possible violations of state laws. If...

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

TPST-1120, a first-in-class, oral, selective PPAR antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune compromised cancersBased on subsequent positive randomized data...

Tempest Therapeutics, Inc. (NASDAQ:TPST) Expected to Post Q1 2024 Earnings of ($0.36) Per Share

Tempest Therapeutics, Inc. (NASDAQ:TPST  Free Report)  HC Wainwright issued their Q1 2024 earnings estimates for Tempest Therapeutics in a report released on Wednesday, March 20th...

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by HC Wainwright

Tempest Therapeutics (NASDAQ:TPST  Get Free Report)s stock had its buy rating restated by HC Wainwright in a research report issued to clients and investors on Wednesday...

Tempest Therapeutics (NASDAQ:TPST) Stock Rating Reaffirmed by William Blair

Tempest Therapeutics (NASDAQ:TPST  Get Free Report)s stock had its outperform rating restated by investment analysts at William Blair in a note issued to investors on...

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Announced positive randomized first-line HCC data showing superiority of TPST-1120 combination therapy across multiple study endpoints compared to standard of careReported new biomarker data in two...

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Tempest Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$10.89
Prev Close	$11.09
Open	$11.09
Dividend Yield	0.00%
50-Day Moving Average	$10.13
Beta	1.89
Avg. Volume	49,396.00
PE Ratio	-0.69

52-Week High	$15.73
52-Week Low	$5.35
Market Capitalization	$45.02M
EPS (Annual)	-$19.50
Price to Book	4.60
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

TPST
Tempest Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TPST News

TPSTTempest Therapeutics Inc